8-K: Hologic Announces Preliminary Q1 Fiscal 2025 Revenue Results, Meeting Guidance

Hologic reported preliminary first-quarter fiscal 2025 revenue of $1,021.8 million, a 0.9% increase year-over-year, aligning with guidance on a constant currency basis.

Summary

• Hologic announced preliminary revenue results for the first quarter of fiscal year 2025, ended December 28, 2024.
• Total revenue is expected to be approximately $1,021.8 million, a 0.9% increase compared to the same period last year.
• On a constant currency basis, revenue increased by 1.0%, which is in line with the company's guidance.
• The strengthening of the U.S. dollar reduced revenue by approximately $9 million compared to the guidance provided in early November.
• GAAP and non-GAAP earnings per share are expected to be near the high end of the previously provided guidance ranges.
• The company will release full financial results for the first quarter on February 5, 2025.
• Updated financial guidance for the second quarter and full year of fiscal 2025 will be provided at the same time.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Revenue met guidance on a constant currency basis, and EPS is expected to be near the high end of guidance. However, there are some negative aspects, such as the impact of currency fluctuations and declines in certain segments.

Positives

• Total revenue met guidance on a constant currency basis.
• Diagnostics division showed strong growth, with a 5.1% increase in revenue.
• Organic Diagnostics revenue, excluding COVID-19, grew by 9.0%.
• GYN Surgical revenue increased by 2.5%.
• The company expects GAAP and non-GAAP EPS to be near the high end of guidance ranges.

Negatives

• The strengthening of the U.S. dollar negatively impacted revenue by approximately $9 million.
• Breast Health revenue decreased by 2.3%.
• Organic Breast Health revenue, excluding SSI and Endomagnetics, decreased by 5.9%.
• Skeletal Health revenue experienced a significant decrease of 37.8%.

Risks

• The company's preliminary results are subject to finalization of quarter-end financial and accounting procedures and may differ materially from actual results.
• The company faces risks related to new competitive technologies, market development, and demand prediction.
• The company is exposed to risks related to healthcare industry consolidation, acquisitions, and third-party payor decisions.
• Regulatory approvals, compliance, and potential product defects pose ongoing risks.
• The company is subject to potential negative impacts from climate change, cybersecurity threats, and supply chain constraints.
• Global challenges, including macroeconomic uncertainties, wars, and political instability, could affect the company's business.

Future Outlook

Hologic expects to provide updated financial guidance for the second quarter and full year of fiscal 2025 when it reports its full first-quarter results on February 5, 2025.

Management Comments

• Karleen Oberton, the Company's Chief Financial Officer, stated that the fiscal Q1 revenue finished in line with guidance on a constant currency basis.
• Karleen Oberton noted that the strengthening of the U.S. dollar reduced revenue by approximately $9 million compared to when guidance was provided in early November.
• Management expects GAAP and non-GAAP earnings per share to be near the high end of guidance ranges.

Industry Context

Hologic's results reflect the ongoing trends in the medical technology industry, including the impact of currency fluctuations and the varying performance of different product segments. The growth in Diagnostics and the decline in Breast Health and Skeletal Health are consistent with broader market dynamics.

Comparison to Industry Standards

• Hologic's 0.9% revenue growth is modest compared to some high-growth medical device companies, but it is in line with expectations given the currency headwinds.
• Companies like Intuitive Surgical (ISRG) and Stryker (SYK) often report higher growth rates, but they operate in different segments.
• The 9.0% growth in organic diagnostics revenue excluding COVID-19 is a positive sign, indicating strong underlying demand in that segment.
• The significant decline in Skeletal Health revenue is concerning and may require further investigation and strategic adjustments.
• The company's performance is comparable to other large medical device companies that have also experienced currency headwinds.

Stakeholder Impact

• Shareholders will be interested in the full financial results and updated guidance to be released on February 5, 2025.
• Employees may be impacted by any strategic changes resulting from the performance of different segments.
• Customers will be interested in the company's ability to continue providing innovative medical technology.
• Suppliers may be affected by any changes in the company's supply chain or manufacturing operations.

Next Steps

• Hologic will provide full financial results for the first quarter on February 5, 2025.
• The company will also provide updated financial guidance for the second quarter and full year of fiscal 2025 on February 5, 2025.
• Hologic will participate in the 43rd Annual J.P. Morgan Healthcare Conference, beginning January 14, 2025.

Key Dates

Keywords

Hologic, Revenue, Diagnostics, Breast Health, GYN Surgical, Skeletal Health, Financial Results, EPS, Constant Currency, Organic Revenue